CN101495486B - 具有抗肿瘤活性的喜树碱衍生物 - Google Patents

具有抗肿瘤活性的喜树碱衍生物 Download PDF

Info

Publication number
CN101495486B
CN101495486B CN2007800283564A CN200780028356A CN101495486B CN 101495486 B CN101495486 B CN 101495486B CN 2007800283564 A CN2007800283564 A CN 2007800283564A CN 200780028356 A CN200780028356 A CN 200780028356A CN 101495486 B CN101495486 B CN 101495486B
Authority
CN
China
Prior art keywords
mmol
nmr
cdcl
acoet
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800283564A
Other languages
English (en)
Chinese (zh)
Other versions
CN101495486A (zh
Inventor
G·丰塔纳
E·邦巴尔代利
C·曼佐蒂
A·巴塔哥利亚
C·萨莫里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN101495486A publication Critical patent/CN101495486A/zh
Application granted granted Critical
Publication of CN101495486B publication Critical patent/CN101495486B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN2007800283564A 2006-07-26 2007-07-13 具有抗肿瘤活性的喜树碱衍生物 Expired - Fee Related CN101495486B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001473A ITMI20061473A1 (it) 2006-07-26 2006-07-26 Derivati della camptotecina ad attivita antitumorale
ITMI2006A001473 2006-07-26
PCT/EP2007/006243 WO2008011994A1 (en) 2006-07-26 2007-07-13 Camptothecin derivatives with antitumor activity

Publications (2)

Publication Number Publication Date
CN101495486A CN101495486A (zh) 2009-07-29
CN101495486B true CN101495486B (zh) 2013-05-15

Family

ID=38668829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800283564A Expired - Fee Related CN101495486B (zh) 2006-07-26 2007-07-13 具有抗肿瘤活性的喜树碱衍生物

Country Status (20)

Country Link
US (1) US8217053B2 (enExample)
EP (1) EP2044079B1 (enExample)
JP (1) JP5313894B2 (enExample)
KR (1) KR101412157B1 (enExample)
CN (1) CN101495486B (enExample)
AU (1) AU2007278500B2 (enExample)
BR (1) BRPI0714553B8 (enExample)
CA (1) CA2658900C (enExample)
DK (1) DK2044079T3 (enExample)
ES (1) ES2561356T3 (enExample)
HU (1) HUE027890T2 (enExample)
IL (1) IL196653A (enExample)
IT (1) ITMI20061473A1 (enExample)
MX (1) MX2009000827A (enExample)
NO (1) NO341812B1 (enExample)
PL (1) PL2044079T3 (enExample)
PT (1) PT2044079E (enExample)
RU (1) RU2450008C2 (enExample)
SI (1) SI2044079T1 (enExample)
WO (1) WO2008011994A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
KR101586030B1 (ko) * 2014-01-22 2016-01-15 주식회사 엘지생활건강 캄프토테신을 유효성분으로 포함하는 체모 성장 억제용 조성물
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
US10568873B1 (en) * 2019-02-14 2020-02-25 United Arab Emirates University Safranal-sorafenib combination therapy for liver cancer
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
IL309457A (en) * 2021-06-17 2024-02-01 Minghui Pharmaceutical Hangzhou Ltd Compound against tumors and its use
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
CN121194979A (zh) * 2023-05-08 2025-12-23 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221421A (zh) * 1996-06-05 1999-06-30 雷迪博士研究基金会 20(s)－喜树碱的新型水溶性c－环类似物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6881555B2 (en) * 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
EP1430059B1 (en) * 2001-09-25 2006-03-01 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of 20(s)-camptothecins
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221421A (zh) * 1996-06-05 1999-06-30 雷迪博士研究基金会 20(s)－喜树碱的新型水溶性c－环类似物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨松等.高喜树碱-极具开发价值的拓扑异构酶I抑制剂.《药学学报》.2004,第39卷(第5期),396-400. *
罗猛等.喜树碱及其衍生物结构修饰及构效关系的研究.《中国药学杂志》.2006,第41卷(第11期),804-806. *

Also Published As

Publication number Publication date
MX2009000827A (es) 2009-02-03
KR101412157B1 (ko) 2014-06-25
PL2044079T3 (pl) 2016-06-30
AU2007278500B2 (en) 2012-06-07
NO341812B1 (no) 2018-01-29
PT2044079E (pt) 2016-03-09
JP5313894B2 (ja) 2013-10-09
US8217053B2 (en) 2012-07-10
IL196653A (en) 2015-04-30
IL196653A0 (en) 2009-11-18
ITMI20061473A1 (it) 2008-01-27
WO2008011994A1 (en) 2008-01-31
CN101495486A (zh) 2009-07-29
CA2658900C (en) 2015-09-15
SI2044079T1 (sl) 2016-02-29
RU2009102243A (ru) 2010-07-27
ES2561356T3 (es) 2016-02-25
KR20090033456A (ko) 2009-04-03
HK1135691A1 (en) 2010-06-11
BRPI0714553A2 (pt) 2013-03-26
NO20090251L (no) 2009-01-16
US20100120816A1 (en) 2010-05-13
JP2009544634A (ja) 2009-12-17
BRPI0714553B8 (pt) 2021-05-25
AU2007278500A2 (en) 2010-09-09
DK2044079T3 (en) 2016-02-29
EP2044079B1 (en) 2015-12-09
CA2658900A1 (en) 2008-01-31
HUE027890T2 (en) 2016-11-28
BRPI0714553B1 (pt) 2020-11-17
EP2044079A1 (en) 2009-04-08
RU2450008C2 (ru) 2012-05-10
AU2007278500A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
CN101495486B (zh) 具有抗肿瘤活性的喜树碱衍生物
AU2007278509B2 (en) Camptothecin derivatives with antitumor activity
HK1135691B (en) Camptothecin derivatives with antitumor activity
JP5198447B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
HK1135692B (en) Camptothecin derivatives with antitumor activity
HK1135693B (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135691

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135691

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130515

CF01 Termination of patent right due to non-payment of annual fee